Head-to-head · WeighScore
Kin Meds vs WeightRx
The verdict
Kin Meds takes it — 72.9/100 to 72.1/100, but only just.
Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and… WeightRx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kin Meds | WeightRx |
|---|---|---|
| WeighScore | 72.9/100 | 72.1/100 |
| Grade | C | C |
| Scorecard rank | #73 | #85 |
| Semaglutide | $149/mo (brand Wegovy) | $250/mo (compounded) |
| Tirzepatide | $149/mo (brand Zepbound) | $83/mo (term not published, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #73 · C
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
Where it loses points
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- Lab work and dose-titration support not clearly described
Graded #85 · C
Strengths
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
Where it loses points
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
- Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
- No dose strength is published anywhere, so what the $83 buys is not stated
- The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.